Third-generation SERMs may face uphill battle.
Charlie
C
Schmidt
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics; D004958:Estradiol / Q000097:blood*; D019317:Evidence-Based Medicine; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000517:prevention & control*; D010330:Patents as Topic; D011322:Primary Prevention / Q000379:methods; D011759:Pyrrolidines / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000187:drug effects / Q000378:metabolism; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D016588:Anticarcinogenic Agents; D050071:Bone Density Conservation Agents; D007211:Indoles; D011759:Pyrrolidines; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013764:Tetrahydronaphthalenes; D013629:Tamoxifen; C111332:Lasofoxifene; D020849:Raloxifene Hydrochloride; D004958:Estradiol; C447119:bazedoxifene